Format

Send to

Choose Destination
Springerplus. 2015 Aug 19;4:428. doi: 10.1186/s40064-015-1217-y. eCollection 2015.

A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Author information

1
Gynecology Service, Anesthesiology Service, Allergy and Immunology Unit and Central Laboratory, 'Eva Peron' Hospital, San Martín, Argentina.
2
Breast Pathology Unit, Italian Hospital, La Plata, Argentina.
3
Thrombosis and Hemostasis Department, National Academy of Medicine, IMEX-ANM, Buenos Aires, Argentina.
4
Pathology Service, Mater Dei Sanatorium, Buenos Aires, Argentina.
5
Elea Laboratories, Buenos Aires, Argentina.
6
Chemo-Romikin, Buenos Aires, Argentina.
7
Laboratorio de Oncología Molecular, Universidad Nacional de Quilmes, R. Sáenz Peña 352, Bernal, B1876BXD Buenos Aires, Argentina.

Abstract

Desmopressin (dDAVP) is a well-known peptide analog of the antidiuretic hormone vasopressin, used to prevent excessive bleeding during surgical procedures. dDAVP increases hemostatic mediators, such as the von Willebrand factor (vWF), recently considered a key element in resistance to metastasis. Studies in mouse models and veterinary trials in dogs with locally-advanced mammary tumors demonstrated that high doses of perioperative dDAVP inhibited lymph node and early blood-borne metastasis and significantly prolonged survival. We conducted a phase II dose-escalation trial in patients with breast cancer, administering a lyophilized formulation of dDAVP by intravenous infusion in saline, 30-60 min before and 24 h after surgical resection. Primary endpoints were safety and tolerability, as well as selection of the best dose for cancer surgery. Secondary endpoints included surgical bleeding, plasma levels of vWF, and circulating tumor cells (CTCs) as measured by quantitative PCR of cytokeratin-19 transcripts. Only 2 of a total of 20 patients experienced reversible adverse events, including hyponatremia (grade 4) and hypersensitivity reaction (grade 2). Reactions were adequately managed by slowing the infusion rate. A reduced intraoperative bleeding was noted with increasing doses of dDAVP. Treatment was associated with higher vWF plasma levels and a postoperative drop in CTC counts. At the highest dose level evaluated (2 μg/kg) dDAVP appeared safe when administered in two slow infusions of 1 μg/kg, before and after surgery. Clinical trials to establish the effectiveness of adjunctive perioperative dDAVP therapy are warranted. This trial is registered on www.clinicaltrials.gov (NCT01606072).

KEYWORDS:

Breast cancer trial; Circulating tumor cells; Hemostasia; Surgery; dDAVP; von Willebrand factor

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center